A New Frontier in Cardiovascular Prevention: Why Lipoprotein(a) May Soon Be Treatable
For decades, lipoprotein(a), commonly abbreviated as Lp(a), has been one of the more frustrating cardiovascular risk factors in preventive medicine. Elevated Lp(a) has long been recognized as an independent contributor to heart disease, yet unlike cholesterol, blood pressure, or diabetes, there has been no treatment specifically designed to lower it.
That may soon be changing.
Several promising therapies are now in advanced clinical trials, bringing us closer than ever to the first medications developed specifically to reduce Lp(a) levels and potentially lower cardiovascular risk.
What Is Lipoprotein(a)?
Lipoprotein(a) is a cholesterol-containing particle that circulates in the bloodstream. Structurally, it resembles LDL cholesterol (“bad cholesterol”) but has an additional protein called apolipoprotein(a) attached to it. This extra component makes Lp(a) particularly concerning because it appears to promote both the buildup of plaque within arteries and inflammation within blood vessels.
Unlike LDL cholesterol, Lp(a) levels are determined almost entirely by genetics. Diet, exercise, and lifestyle changes have relatively little impact on the amount your body produces.
Approximately 10% of the population has significantly elevated Lp(a), generally defined as greater than 50 mg/dL (approximately 125 nmol/L). Individuals with elevated levels have a substantially higher lifetime risk of:
Coronary artery disease
Heart attacks
Stroke
Aortic valve stenosis
Premature cardiovascular disease, even in otherwise healthy individuals
Because Lp(a) is inherited, elevated levels often run in families.
Why Has It Been So Difficult to Treat?
Until recently, physicians could identify elevated Lp(a), but there were few effective ways to lower it.
Traditional cholesterol-lowering medications such as statins provide tremendous cardiovascular benefit, but they do not significantly reduce Lp(a). PCSK9 inhibitors can modestly lower Lp(a), typically by about 20 to 30 percent, but they were developed primarily to lower LDL cholesterol rather than target Lp(a) specifically.
As a result, treatment has focused on aggressively controlling every other cardiovascular risk factor, including LDL cholesterol, blood pressure, diabetes, smoking, weight, and exercise.
A New Generation of Targeted Therapies
Researchers are now studying several medications designed specifically to reduce Lp(a) production in the liver.
The most advanced candidates include:
Pelacarsen – an antisense oligonucleotide currently in Phase 3 clinical trials with results expected soon.
Olpasiran – an siRNA therapy also in Phase 3 testing that has demonstrated dramatic reductions in Lp(a) levels.
Lepodisiran – another siRNA therapy notable for its potential to maintain very low Lp(a) levels for many months after a single injection.
Muvalaplin – the first oral medication being studied for Lp(a), currently in Phase 2 trials.
Zerlasiran – another promising siRNA therapy currently in Phase 2 development.
Many of these investigational medications have demonstrated reductions in Lp(a) exceeding 80 to 90 percent in early clinical studies. The critical question now is whether lowering Lp(a) translates into fewer heart attacks, strokes, and cardiovascular deaths. Large outcome trials currently underway are designed to answer that question.
If the data remain favorable, the first FDA approval could occur as early as 2027.
Should You Be Tested?
Many cardiologists and preventive medicine specialists now recommend that adults have Lp(a) measured at least once during their lifetime, particularly if they have:
A family history of early heart disease
Elevated cholesterol despite treatment
Heart disease without traditional risk factors
A personal or family history of unexplained cardiovascular events
Aortic valve stenosis
Because Lp(a) is genetically determined and remains relatively stable throughout life, a single measurement is often sufficient.
The Bottom Line
The field of cardiovascular prevention continues to evolve rapidly. While elevated Lp(a) has historically represented a risk factor physicians could identify but not directly treat, that reality may soon change.
For individuals with genetically elevated Lp(a), these emerging therapies represent one of the most exciting developments in preventive cardiology in decades. As clinical trial results become available over the next year, they may reshape how we assess and manage inherited cardiovascular risk.
At Williams + Weiss Executive Medicine, we believe that personalized prevention begins with understanding each patient’s unique risk profile. Advanced cardiovascular testing, including Lp(a) when appropriate, allows us to identify inherited risk factors early and develop evidence-based strategies to reduce long-term cardiovascular disease.